Cite
Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib.
MLA
Schafhausen, Philippe, et al. “Development of AML with t(8;21)(Q22;Q22) and RUNX1-RUNX1T1 Fusion Following Philadelphia-Negative Clonal Evolution during Treatment of CML with Imatinib.” Cancer Genetics and Cytogenetics, vol. 189, no. 1, Feb. 2009, pp. 63–67. EBSCOhost, https://doi.org/10.1016/j.cancergencyto.2008.09.016.
APA
Schafhausen, P., Dierlamm, J., Bokemeyer, C., Bruemmendorf, T. H., Bacher, U., Zander, A. R., Schnittger, S., & Hochhaus, A. (2009). Development of AML with t(8;21)(q22;q22) and RUNX1-RUNX1T1 fusion following Philadelphia-negative clonal evolution during treatment of CML with Imatinib. Cancer Genetics and Cytogenetics, 189(1), 63–67. https://doi.org/10.1016/j.cancergencyto.2008.09.016
Chicago
Schafhausen, Philippe, Judith Dierlamm, Carsten Bokemeyer, Tim H Bruemmendorf, Ulrike Bacher, Axel R Zander, Susanne Schnittger, and Andreas Hochhaus. 2009. “Development of AML with t(8;21)(Q22;Q22) and RUNX1-RUNX1T1 Fusion Following Philadelphia-Negative Clonal Evolution during Treatment of CML with Imatinib.” Cancer Genetics and Cytogenetics 189 (1): 63–67. doi:10.1016/j.cancergencyto.2008.09.016.